Atreca, Inc. (BCEL) gained in the current market after announcing its participation in Cowen’s 42nd Annual Healthcare Conference. BCEL values at $2.36, gaining more than 41.34% compared to yesterday’s closing price. The stock closed at $1.67 at the end of the last trading session. The stock volume traded in the previous trading session was around 323.95k shares. The current market cap of the company is about $85.45 million.
BCEL: Newz Update
In a press release today, Atreca, Inc. (BCEL) announced that John Orwin, President, and CEO, would participate in a panel discussion at Cowen’s 42nd Annual Healthcare Conference. The Cowen’s 42nd Annual Healthcare Conference will be happening on March 7-9, 2022.
BCEL: Key Financials
- R&D expenses in fiscal 2021 were $78.3 million. R&D in the fourth quarter was around $22.2 million.
- General and administrative expenses in fiscal 2021 were $32.0 million and $7.3 million in the fourth quarter.
- BCEL reported a net loss of around $109.3 million in fiscal 2021. The company reported a $29.5 million net loss in the fourth quarter.
- EPS in fiscal 2021 was $2.95 and 0.79 in the fourth quarter.
BCEL: ATRC-101 Update
Among patients with certain solid tumor malignancies, the Phase 1b trial will be the first human evaluation of ATRC-101. In the monotherapy and combination dose-escalation groups, ATRC-101 was well tolerated, with no dose-limiting toxicities reported. On average, 6 (34%) of the 47 individuals had an adverse event of grade 3. (AE). Participation is still open in the Q3W and Q2W monotherapy and pembrolizumab combination cohorts. It expects to start participant selection based on target expression in 2Q22. 2H22 data for monotherapy and combination are expected from Atreca.
Conclusion
The stock of the company is gaining in today’s trading session. Investors responded positively to its participation in Cowen’s 42nd Annual Healthcare Conference. The stock is also gaining due to its update on ATRC-101 and Q4 and fiscal 2021 results.
